AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Merck KGaA Plans $4 Billion Bond Sale to Fund SpringWorks Acquisition
ByAinvest
Monday, Aug 11, 2025 5:08 pm ET1min read
Merck KGaA plans to sell $4 bln of bonds to fund its acquisition of SpringWorks Therapeutics. The deal will be split into four parts with maturities ranging from 3 to 10 years. Proceeds will be used to refinance temporary debt for the $3.9 bln acquisition. The company has asked banks to arrange calls with investors starting Monday. Merck KGaA expects the acquisition to close in the second half of the year.
Merck KGaA, a German pharmaceutical and electronics conglomerate, is set to issue around $4 billion in US investment-grade bonds to finance its acquisition of SpringWorks Therapeutics Inc. According to sources familiar with the matter, the deal will be structured into four parts, with maturities ranging from three to ten years. Proceeds from the bond sale will be used to refinance the temporary debt incurred during the $3.9 billion acquisition of SpringWorks, a biopharmaceutical company [1].The company has requested that banks including Barclays Plc, BBVA SA, Bank of America Corp., JPMorgan Chase & Co., and Societe Generale SA arrange calls with bond investors starting on Monday. Representatives for JPMorgan, Bank of America, and Barclays declined to comment, while the other firms were not immediately available for comment. Merck KGaA has not yet commented on the matter outside of European business hours [1].
This bond sale comes shortly after Merck KGaA lowered its full-year sales growth forecast, citing a weaker dollar and a slowdown in its electronics business. The company had previously indicated that it expects the acquisition of SpringWorks to close in the second half of this year [1].
In the second quarter of 2025, Merck KGaA reported a 4.6% organic EBITDA pre growth, driven by increased sales of multiple sclerosis and oncology drugs, as well as continued demand for semiconductor materials. The company now expects 2025 organic EBITDA pre growth of 4% to 8%, up from its previous forecast of 2% to 7% [2].
The acquisition of SpringWorks Therapeutics, completed on July 1, 2025, has expanded Merck KGaA's rare tumor pipeline. On July 18, the European Commission conditionally approved Ezmekly (mirdametinib), developed by SpringWorks, for treating inoperable plexiform neurofibromas [2].
References:
[1] https://www.bloomberg.com/news/articles/2025-08-11/merck-kgaa-is-said-to-plan-4-billion-bond-sale-to-fund-purchase
[2] https://www.investing.com/news/earnings/merck-kgaa-lifts-2025-profit-outlook-after-strong-drug-ai-material-sales-in-q2-4175019
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet